HER2, also known as erb-b2 receptor tyrosine kinase 2 (ERBB2), is a transmembrane tyrosine kinase receptor that is overexpressed in around 20% of all breast cancers, leading to a poor prognosis for patients (1, 2). This evidence concerns the gene ERBB2 and breast carcinoma.